<a href="https://www.fiercebiotech.com/biotech/parabilis-fresh-inking-regeneron-pact-plans-ipo-fund-tumor-drugs-phase-3-push" hreflang="en">Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push</a>
fiercebiotech.com·May 20, 2026
Parabilis Medicines plans to launch an IPO to fund a phase 3 study of its tumor drug, zolucatetide, following a recent partnership with Regeneron. The company aims to use IPO proceeds for further clinical trials and to advance its helicon peptide platform, despite already having substantial cash reserves.
Parabilis Medicines is planning an IPO to fund its phase 3 study of zolucatetide, a Wnt/β-catenin pathway inhibitor for desmoid tumors, which has received FDA fast-track designation. This move, coupled with a substantial $50 million upfront payment and $75 million equity investment from Regeneron, signals strong financial backing and strategic alignment, making Parabilis a compelling investment opportunity in the oncology biotech space.